Child psychiatry and its relationship with the pharmaceutical industry: Theoretical and practical issues

Advances in Psychiatric Treatment

Volumn 14, Issue 1, 2008, Pages 3-9

  Timimi, Sami ^a,b  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b UNIVERSITY OF LINCOLN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; FLUOXETINE; METHYLPHENIDATE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CHILD; CHILD HEALTH; CHILD PSYCHIATRY; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUSTRY; DRUG QUALITY; DRUG RELEASE; DRUG SAFETY; EDITORIAL; EMOTIONAL DISORDER; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; MEDICAL ETHICS; MENTAL HEALTH; MENTAL HEALTH CARE; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRESCRIPTION; PROFESSIONAL DEVELOPMENT; PSYCHIATRIST; SOCIAL SUPPORT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 58049127387     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.105.000901     Document Type: Editorial

References (42)

1. Attention Deficit Disorder Information and Support Service (2007) Lessons 4 Life. ADDISS. http://www.addiss.co.uk/ lessonsforlife.pdf
2. Baker, C. B., Johnsrud, M. T., Crimson, M. L., et al (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry, 183, 498-506.
3. Boyd, E. A. & Bero, L. A. (2000) Assessing faculty financial relationships with industry. JAMA, 284, 2209-2214.
4. Boyle, M. H. & Jadad, A. R. (1999) Lessons from large trials: the MTA study as a model for evaluating the treatment of childhood psychiatric disorder. Canadian Journal of Psychiatry, 44, 991-998.
5. Breggin, P. (2000) The NIMH multimodal study of treatment for attention deficit/hyperactivity disorder: a critical analysis. International Journal of Risk and Safety in Medicine, 13, 15-22.
6. Department of Health (2000) 'Prescription Cost Analysis: England 1999'. Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/ Statistics/StatisticalWorkAreas/Statisticalhealthcare/DH_4015574
7. Department of Health (2007) 'Prescription Cost Analysis: England 2006'. Department of Health. http://www.ic.nhs.uk/webfiles/publications/ pca2006/PCA_2006.pdf
8. Emslie, G. J., Heiligenstein, J., Wagner, K.D., et al (2002) Fluoxetine for acute treatment of depression in children and adolescents. A placebocontrolled, randomized clinical trial. Journal of American Academy of Child and Adolescent Psychiatry, 41, 1205-1215.
9. Emslie, G. J., Rush, A. J., Weinberg, W. A., et al (1997) A doubleblind, randomized, placebocontrolled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031-1037.
10. European Medicines Agency (2005) 'European Medicines Agency finalises review of antidepressants in children and adolescents'. EMA. http://www.emea.eu.int/pdfs/human/press/pr/12891805en.pdf
11. Goodman, R. (1997) An over extended remit. BMJ, 314, 813-814.
12. Healy, D. (2003) Conspiracy of consensus. Mental Health Today, November, 27-30.
13. Hearn, K. (2004) 'Here kiddie, kiddie'. AlterNet. http://alternet.org/ drugreporter/20594
14. Jackson, G. (2005) Rethinking Psychiatric Drugs. AuthorHouse.
15. Jensen, P., Arnold, E., Swanson, J., et al (2007) 3 year follow-up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 988-1001.
16. Jureidini, J. & Mansfield, P. R. (2006) The scope of the problem of the relationship between drug companies and doctors. In Critical Voices in Child and Adolescent Mental Health (eds S. Timimi & B. Maitra), pp. 37-47. Free Association Books.
17. Jureidini, J., Doecke, C., Mansfield, P. R., et al (2004a) Efficacy and safety of antidepressants for children and adolescents. BMJ, 328, 879-883.
18. Jureidini, J., Tonkin, A. & Mansfield, P. R. (2004b) TADS study raises concerns. BMJ, 329, 1343-1344.
19. Kmietowicz, Z. (2005) NHS criticised for lax control over drugs industry. BMJ, 330, 805.
20. Leo, J. (2006) The truth about academic medicine: children on psychotropic drugs and the illusion of science. In Critical Voices in Child and Adolescent Mental Health (eds S. Timimi & B. Maitra), pp. 115-135. Free Association Books.
21. March, J. S., Silva, S., Petrycki, S., et al (2007) The Treatment for Adolescents With Depression Study (TADS): long-term-effectiveness and safety outcomes. Archives of General Psychiatry, 64, 1132-1143.
22. Medawar, C. & Hardon, A. (2004) Medicines out of Control? Antidepressants and the Conspiracy of Goodwill. Aksant Academic.
23. Melander, H., AhlqvistRastad, I., Meijer, G., et al (2003) Evidence b(i)ased medicine - selective reporting from studies sponsored by the pharmaceutical industry: review of studies in new drug applications. BMJ, 326, 1171-1173.
24. Mintzes, B. (2002) Direct to consumer advertising is medicalising normal human experience. BMJ, 324, 908-911.
25. Moncrieff, J. (2003) Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a reexamination. British Journal of Psychiatry, 183, 161-166.
26. Moynihan, R. (ed.) (2003) BMJ Special Issue, 326, 1155-1222.
27. MTA Cooperative Group (1999) A 14 month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
28. MTA Cooperative Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attentiondeficit/hyperactivity disorder. Pediatrics, 113, 754-761.
29. Olfson, M., Marcus, S. C., Weissman, M. M., et al (2002) National trends in the use of psychotropic medications by children. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 514-521.
30. Orlowski, J. P. & Wateska, L. (1992) The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. Chest, 102, 270-273.
31. Public Citizen's Congress Watch (2002) America's Other Drug Problem: A Briefing Book on the Rx Drug Debate. Public Citizen. http://www.citizen.org/documents/drugbriefingbk.pdf
32. Rabiner, D. (2004) New results from the MTA study - do treatment effects persist? Attention Research Update, June. http://www.helpforadd.com/2004/june.htm
33. Ramchandani, P. (2004) Treatment of major depressive disorder in children and adolescents. BMJ, 328, 3-4.
34. Safer, D. J. (2002) Design and reporting modifications in industry sponsored comparative psychopharmacology trials. Journal of Nervous and Mental Disease, 190, 583-592.
35. Sagarin, B. J., Cialdini, R. B., Rice, W. E., et al (2002) Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion. Journal of Personal and Social Psychology, 83, 526-541.
36. Treatment for Adolescents with Depression Study Team (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial. JAMA, 292, 807-820.
37. Timimi, S. (2002) Pathological Child Psychiatry and the Medicalization of Childhood. Brunner-Routledge.
38. Timimi, S. (2005) Naughty Boys: Anti-Social Behaviour, ADHD and the Role of Culture. Palgrave-MacMillan.
39. Wazana, A. (2000) Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA, 283, 373-380.
40. Whittington, C. J., Kendall, T., Fonagy, P., et al (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet, 363, 1341-1345.
41. Wong, I. C., Murray, M. L., Camilleri-Novak, D., et al (2004) Increased prescribing trends of paediatric psychotropic medica tions. Archives of Disease in Childhood, 89, 1131-1132.
42. Zito, J. M., Safer, D. J., Dosreis, S., et al (2000) Trends in prescribing of psychotropic medication in pre-schoolers. JAMA, 283, 1025-1030.